Cingulate Inc Dossier - Source-backed chat

Cingulate Inc

CINGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.26

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.75Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $69.1M

Enterprise Value $46.8M

Shares Outstanding 12.5M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cingulate Inc. is a clinical-stage biopharmaceutical company whose investment profile is highly binary, centered on the regulatory approval and commercialization of its lead ADHD asset, CTx-1301. The company recently faced a late-stage regulatory setback on June 2, 2026, when the FDA issued a Complete Response Letter (CRL) for CTx-1301. Crucially, the CRL did not identify any clinical safety or efficacy concerns, narrowing the outstanding issues entirely to Chemistry, Manufacturing, and Controls (CMC) information requests. While the company is well-capitalized with nearly $30 million in cash to address these issues and sustain operations into 2027, commercial launch is delayed from the original target. A 'Hold' recommendation is advised until the company provides a clear timeline for NDA resubmission and demonstrates successful remediation of manufacturing partner observations.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$23.00

High · most bullish analyst$52.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0015%

The manufacturing and CMC deficiencies cited in the CRL and the underlying Form 483 observations at the CDMO facility prove more complex and time-consuming to resolve than anticipated. This leads to prolonged delays in NDA resubmission or a second CRL. As the regulatory timeline stretches into late 2027, Cingulate rapidly burns through its cash reserves, forcing highly dilutive equity issuances at depressed share prices. In the worst-case scenario, the inability to secure approval for CTx-1301 halts the development of pipeline assets (CTx-1302 and CTx-2103) and threatens the company's viability as a going concern.

Base CaseCentral scenario

$5.0050%

Cingulate will spend the remainder of 2026 working closely with its CDMO to compile and submit the requested CMC data to the FDA. The resubmission is expected by late 2026 or early 2027, pushing the potential FDA approval decision to mid-2027 and delaying the commercial launch to late 2027 or early 2028. The company's current cash reserves of nearly $30 million provide sufficient runway to complete this process without immediate insolvency, but ongoing cash burn of ~$7 million per quarter will necessitate further dilutive capital raises under its ATM or Lincoln Park facilities before commercial revenues can be realized.

Bull CaseUpside scenario

$20.0035%

The FDA's CRL is strictly limited to CMC requests, leaving the robust Phase 3 clinical efficacy and safety data unchallenged. CTx-1301's proprietary Precision Timed Release (PTR) platform successfully delivers three precisely timed releases of dexmethylphenidate, achieving rapid onset (within 30 minutes) and active-day symptom control (up to 16 hours) to eliminate midday rebound effects. If Cingulate and its CDMO partner, Bend Bio Sciences, promptly resolve the CMC requests, the NDA could be approved within 6 months of resubmission. This would pave the way for a successful commercial launch in 1H 2027, targeting a highly lucrative $20B+ US ADHD market with a clinically differentiated product.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

No clinical safety or efficacy concerns were raised by the FDA in the CTx-1301 CRL, preserving the asset's strong clinical profile.
Proprietary Precision Timed Release (PTR) platform offers genuine clinical differentiation by providing true once-daily dosing and eliminating midday rebound.
Strong intellectual property protection with the first wholly-owned U.S. patent for CTx-1301 issued in June 2026, extending exclusivity to December 2042.
Improved short-term liquidity with nearly $30 million in cash reserves, providing runway into 2027 to address regulatory hurdles.

Key Investment Risks

Regulatory delay following the June 2026 CRL, pushing back the commercialization timeline and revenue generation.
High dependency on third-party CDMO (Bend Bio Sciences) to resolve manufacturing deficiencies and FDA Form 483 observations.
Significant ongoing cash burn (~$7 million per quarter) and history of operating losses.
Risk of substantial shareholder dilution from future reliance on ATM offerings and stock purchase agreements to fund operations.

Thesis Invalidation Triggers

Failure to resubmit the CTx-1301 NDA within the next 9 months.
Receipt of a second CRL or additional clinical trial requirements from the FDA.
Severe cash depletion below $10 million without securing non-dilutive strategic partnerships or licensing deals.
Inability to maintain compliance with Nasdaq listing requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.